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Commentary: Statins and fracture
risk—unresolved questions
Christoph R Meier
In 2000, we found a substantially reduced fracture risk for
patients who used hydroxymethyl-glutaryl coenzyme A
reductase inhibitors, a class of lipid-lowering drugs also called
‘statins’
1
in a retrospective nested case–control analysis using
data from the British General Practice Research Database
(GPRD). Two large US-based epidemiological analyses reported
virtually the same findings.
2,3
These studies were stimulated by
an intriguing paper by Mundy et al. who screened numerous
pharmacological compounds in an animal model. They found a
marked increase in bone mass in simvastatin-treated rodents.
4
A recent review article by Bauer
5
nicely summarized these as
well as numerous subsequent observational studies: most of
them consistently found a reduced fracture risk for human
statin users. In 2001, a Dutch group used the GPRD to revisit
this issue: they concluded that ‘use of statins at dosages
prescribed in clinical practice was not associated with a
reduction in risk of fracture’.
6
In the current issue of the IJE, Frank de Vries, a co-author of
the second GPRD analysis,
6
reports on a re-analysis of GPRD
data. The focus is on hip fractures and on explaining the
differing results. The first two studies using GPRD data
1,6
differed in four aspects: First, we conducted a nested case–
control analysis including 3940 fracture cases and 23 379
controls, all of which came from a study population of users of
lipid-lowering drugs, patients with untreated hyperlipidaemia,
or a random sample of the GPRD population which had neither
hyperlipidaemia nor use of lipid-lowering drugs recorded.
1
Van Staa et al. did an open case–control analysis in the GPRD
and included virtually all fracture cases .50 years of age:
81 880 fracture cases and the same number of controls.
6
Second, the Dutch group used a larger version of the GPRD,
which included data from 683 general practices, while we used
a copy of the GPRD with only about half of these practices.
We eliminated, independent from this particular study ques-
tion, all practices for which data quality was uncertain. Third,
we a priori excluded participants with cancer, osteoporosis,
alcoholism, or previous use of bisphosphonates, while van Staa
et al. did not make any exclusions. Finally, current statin users
in our study had their last statin prescription recorded ,30 days
prior to the index date, while the Dutch group classified
patients as current users if they had a statin prescription
recorded within 6 months prior to the index date.
De Vries addresses some of these issues in his re-analysis.
The study design (‘selected population’ vs ‘entire population’),
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however, does not seem to make a substantial difference, since
the results for hip fractures are closely similar, and, interest-
ingly, also quite similar to what Meier
1
and van Staa
6
reported
a few years ago (Table 1). De Vries explores what may have
caused these subtle differences by using various exposure
categories for statins and by applying matching for age in
different ways. However, none of these modifications made a
substantial difference, which is a useful piece of information in
its own right. Thus, his re-analysis can be interpreted as
providing evidence that modifying certain factors in the design
or analysis can shift the odds ratio upwards or downwards,
leading to differences in the interpretation of results. On the
other hand, one could also argue that unsurprisingly point
estimates change slightly when certain conditions are modified,
but this change (for example from an odds ratio of 0.4–0.5) is
not relevant in the big picture. In contrast to De Vries, I am
not impressed by the magnitude of changes in the odds ratios
after modifying these parameters, including the age-bands in
the matching procedure.
De Vries discusses the possibility that the statin–fracture
association may be distorted by socioeconomic status (SES), a
parameter which is hard to measure and which was only taken
indirectly into account in the GPRD studies by matching on
practice. Indeed, it is conceivable, as discussed in our report,
1
that people with higher SES may a priori have a lower fracture
risk and a higher likelihood of receiving statins. Unfortunately,
the current re-analysis cannot solve this question. Another
observation made by de Vries has to be seen in the same
context: in our paper
1
as well as his re-analysis, few statin
prescriptions were already associated with a reduced fracture
risk, even though one might expect an effect only after several
months of treatment. One explanation may be bias or
substantial confounding, for example by SES: if statin users
have a priori a lower fracture risk than non-users, one would
expect a reduced fracture risk for all statin users, regardless of
exposure timing or duration. However, we also explored
whether the fracture risk differed between current statin users
and past statin users; for all fractures combined, the OR for
current statin use was 0.55 [95% confidence interval (95% CI)
0.44–0.69], and 0.87 (95% CI 0.65–1.18) for past statin use.
1
These results do not rule out bias associated with statin use, but
reduce these worries to some degree. Another explanation
might be an immediate effect on bones, since bisphosphonates
also exert an effect within a few weeks of a therapy initiation.
Finally, we may measure a real effect of statins on fracture
risk, but this might not be caused by increasing bone strength
but by reducing the risk of falls: statins could reduce the risk of
falls by improving microcirculation in the brain and thereby
co-ordination and propiception. This is not easy to study in an
observational setting since falling is not a hard endpoint. To
my knowledge, there is only one small study on the risk of
falls in relation to statin use which does not support this
hypothesis,
7
but nevertheless we need to keep our eyes open
for alternative explanations of intriguing und unexpected
observations in epidemiological studies.
A reduced fracture risk associated with current statin use has
been seen consistently in numerous observational studies,
which were done by independent research groups in various
health systems and different parts of the world. This surely tells
us something, and it seems unlikely that these findings are
entirely the result of chance or bias. One important question,
however, remains unsolved: why have the various re-analyses
of data from randomized trials
8–11
not supported the same
conclusions? As much as I support De Vries’ attempt to answer
some of the open questions I am afraid that the current
re-analysis does not help much regarding this key question.
Hopefully a future large, well-designed randomized trial, done
in an appropriate study population with prospective bone
density measurements and fractures as the primary outcome
will ultimately provide the answer.
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Table 1 Current statin use compared with non-use: Results from different analyses of the General Practice Research Database (GPRD)
Study Odds ratio (95% CI) Comment
Meier et al.
1
0.12 (0.04–0.41) Based on 3 exposed cases and 77 exposed controls
Van Staa et al.
6
0.59 (0.31–1.13) Based on 18 exposed cases and 31 exposed controls
De Vries (in this issue)
‘Selected population’ 0.37 (0.27–0.52) Based on 67 exposed cases and 542 exposed controls, approach similar to Ref. (1)
‘Entire population’ 0.54 (0.39–0.74) Based on 58 exposed cases and 106 exposed controls, approach similar to Ref. (6)
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